Cefotaxime

Overview

Cefotaxime (Claforan®) is a third-generation cephalosporin antibiotic administered parenterally in dogs and cats when a broad-spectrum, injectable beta-lactam is indicated. It exhibits bactericidal, time-dependent activity and is primarily reserved for serious infections requiring systemic therapy.

Cefotaxime is not appreciably absorbed after oral administration and must be given IV, IM, or SC to achieve therapeutic concentrations. It distributes widely into body tissues, including bone, body fluids, and inflamed meninges, allowing therapeutic cerebrospinal fluid concentrations when high doses are used in cases of meningitis.

Mechanism of Action (MOA):
Like other cephalosporins, cefotaxime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. It has extended activity against many gram-negative aerobes (including Enterobacterales such as E. coli and Klebsiella spp.) while maintaining activity against many gram-positive cocci (excluding Enterococcus spp.). It is ineffective against methicillin-resistant staphylococci, ESBL-producing organisms, and Pseudomonas aeruginosa.

Indications

Cefotaxime is used in dogs and cats when a parenteral third-generation cephalosporin is indicated for treatment of serious or life-threatening bacterial infections caused by susceptible organisms. Because it is classified as a critically important antimicrobial, its use should be reserved for cases in which culture and susceptibility results or clinical judgment justify its selection.

• Sepsis and severe systemic infections:
  Empiric or culture-directed therapy for suspected or confirmed bacterial sepsis caused by susceptible gram-negative or gram-positive organisms.
• Bone and joint infections:
  Treatment of osteomyelitis or septic arthritis when organisms are susceptible and parenteral therapy is required.
• Central nervous system infections:
  May be considered in cases of bacterial meningitis, as therapeutic CSF concentrations can be achieved when meninges are inflamed.
• Surgical prophylaxis:
  Used perioperatively in selected high-risk procedures where extended gram-negative coverage is desired.
• Deep or complicated infections:
  Such as severe soft tissue infections or infections involving body cavities, when broad-spectrum injectable therapy is indicated.

Dosage (Reference)

Dog

In dogs, several dosing regimens have been suggested in the literature. Selection of dose and interval should be based on infection severity, suspected organism, and patient renal function.

Cat

In cats, suggested dosing regimens are similar to those used in dogs. Selection should consider infection severity and renal function.

Warnings & Precautions

Cefotaxime should be used judiciously and reserved for infections in which a parenteral third-generation cephalosporin is clearly indicated. Careful patient selection and monitoring are recommended.

• Hypersensitivity:
  Contraindicated in patients with a known hypersensitivity to cephalosporins. Because cross-reactivity may occur, use cautiously in animals with a history of allergy to other beta-lactam antibiotics (e.g., penicillins, carbapenems).
• Renal impairment:
  Patients with significant renal dysfunction may require dosage adjustment due to primary renal excretion of the drug and its metabolites.
• Administration rate (IV):
  Rapid IV administration has been associated with potentially serious arrhythmias in humans; administer IV doses slowly.
• Injection site reactions:
  IM administration may be painful and can occasionally result in local inflammation or sterile abscess formation.
• Superinfection risk:
  Alteration of normal gastrointestinal flora may allow proliferation of resistant organisms and development of antibiotic-associated diarrhea.
• Neurotoxicity (high doses or prolonged use):
  Excessive or extended therapy has been associated with neurologic effects in some species.
• Drug name confusion:
  Cefotaxime may be confused with other cephalosporins; ensure accurate prescribing and dispensing.

Drug Interactions

Cefotaxime may interact with other medications that affect renal function, anticoagulation pathways, or tubular secretion. When used concurrently, appropriate monitoring is recommended.

• Aminoglycosides (e.g., gentamicin):
  May increase the risk of nephrotoxicity when used together; monitor renal function closely. However, synergistic antibacterial effects against certain gram-negative organisms may occur.
• Other nephrotoxic drugs (e.g., amphotericin B, furosemide):
  Concurrent administration may increase the risk of renal injury; use cautiously and monitor renal parameters.
• Probenecid:
  Inhibits renal tubular secretion of cephalosporins, increasing serum concentrations and prolonging elimination half-life.
• Vitamin K antagonists (e.g., warfarin):
  Cephalosporins may enhance anticoagulant effects; monitor for signs of altered coagulation.

Side Effects & Overdose

Side Effects

Adverse effects associated with cefotaxime are generally uncommon and typically mild, but hypersensitivity and gastrointestinal disturbances may occur.

• Injection site reactions:
  Pain is common after IM administration; inflammation, thrombophlebitis (IV), or rarely sterile abscess formation may occur.
• Gastrointestinal effects:
  Diarrhea may develop due to alteration of normal intestinal flora; superinfection with resistant organisms is possible.
• Hypersensitivity reactions:
  May include rash, fever, eosinophilia, lymphadenopathy, or anaphylaxis; unrelated to dose.
• Hematologic abnormalities (rare, usually high dose or prolonged use):
  Neutropenia, agranulocytosis, thrombocytopenia, or positive Coombs test have been reported.
• Renal effects (rare):
  Interstitial nephritis or tubular necrosis may occur, particularly with concurrent nephrotoxic agents.
• Neurotoxicity (high doses/prolonged therapy):
  Neurologic signs may occur in rare cases.

Overdose

Significant toxicity following cefotaxime overdose is uncommon. However, exaggerated adverse effects may occur, particularly neurologic or renal complications.

• Expected findings:
  Increased risk of gastrointestinal upset, hypersensitivity reactions, or neurologic signs at very high doses.
• Management:
  Provide supportive care as indicated. Monitor renal function and neurologic status in suspected significant overdoses.

Key Notes

Practical clinical considerations for the appropriate use of cefotaxime in dogs and cats:

• Time-dependent antibiotic:
  Clinical efficacy depends on maintaining drug concentrations above the minimum inhibitory concentration (MIC); adherence to dosing interval is important.
• CSF penetration:
  Therapeutic concentrations can be achieved in inflamed meninges, making it a potential option in selected CNS infections.
• Not effective against certain organisms:
  Ineffective against ESBL-producing organisms, methicillin-resistant staphylococci, and Pseudomonas aeruginosa; culture and susceptibility testing are strongly recommended.
• Partial hepatic metabolism:
  Forms an active metabolite (desacetylcefotaxime), which contributes to antibacterial activity.
• Primary renal elimination:
  Most of the drug and its metabolites are excreted in urine; renal function influences drug clearance.
• Not orally bioavailable:
  Must be administered parenterally to achieve therapeutic serum concentrations.